Olema Pharmaceuticals, Inc. (OLMA) Income Statement
OLMA 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsOLMA revenue and net income
OLMA growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | — | — | — | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
OLMA quarterly EPS vs estimates
Olema Pharmaceuticals beat the analyst EPS estimate in 3 of the last 8 quarters. Next report: November 9, 2026 (estimate $-0.60).
OLMA income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | — | $393,000 | $377,000 | $1.7M | $1.7M | $11,000 | $9,033 | $8,244 |
| Gross profit | — | −$393,000 | −$377,000 | −$1.7M | −$1.7M | −$11,000 | −$9,033 | −$8,244 |
| Research & development | $157.7M | $124.5M | $86.1M | $82.3M | $51.1M | $13.7M | $3.9M | $1.7M |
| Sales, general & admin | $21.0M | $17.7M | $19.2M | $24.7M | $20.4M | $7.8M | $403,000 | $386,000 |
| Total operating expenses | $178.7M | $142.3M | $105.0M | $107.0M | $71.5M | $21.5M | $4.3M | $2.1M |
| Operating income | −$178.7M | −$142.3M | −$105.0M | −$107.0M | −$71.5M | −$21.5M | −$4.3M | −$2.1M |
| Interest income | $16.2M | $12.7M | $5.7M | $2.2M | $442,000 | $60,000 | $7,000 | $4,000 |
| Interest expense | — | — | — | $357,000 | $232,000 | $653,000 | $0 | $28,000 |
| Income before taxes | −$162.5M | −$129.5M | −$96.7M | −$104.8M | −$71.1M | −$22.1M | −$4.3M | −$2.2M |
| Income taxes | — | −$1 | — | −$2.2M | −$210,000 | $642,000 | −$155,860 | −$90,000 |
| Net income | −$162.5M | −$129.5M | −$96.7M | −$102.6M | −$71.1M | −$22.1M | −$4.3M | −$2.2M |
| EBITDA | −$162.0M | −$129.1M | −$96.3M | −$106.6M | −$70.9M | −$21.5M | −$4.3M | −$2.1M |
| EPS (diluted) | −$1.86 | −$2.21 | −$2.16 | −$2.62 | −$1.80 | −$0.53 | −$0.31 | −$0.73 |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $364,000 | $0 | $0 | $0 | $1.9M | $0 |
| Cost of revenue | — | $119,000 | $187,000 | — | — | $128,000 | $182,000 | $95,000 | $94,000 | $88,000 | $88,000 | $90,000 |
| Gross profit | — | −$119,000 | −$187,000 | — | — | −$128,000 | $182,000 | −$95,000 | −$94,000 | −$88,000 | $1.8M | −$90,000 |
| Research & development | $57.8M | $49.2M | $43.2M | $40.0M | $43.9M | $30.6M | $32.3M | $33.2M | $29.1M | $29.9M | $25.9M | $19.5M |
| Sales, general & admin | $9.4M | $8.9M | $6.9M | $5.9M | $4.0M | $4.2M | $4.5M | $4.4M | $4.5M | $4.5M | $4.6M | $3.9M |
| Total operating expenses | $67.2M | $57.9M | $49.9M | $45.9M | $47.9M | $34.9M | $36.8M | $37.6M | $33.5M | $34.3M | $30.4M | $23.3M |
| Operating income | −$67.2M | −$58.0M | −$50.1M | −$45.9M | −$47.9M | −$34.9M | −$36.8M | −$37.6M | −$33.5M | −$34.3M | −$30.4M | −$23.3M |
| Interest income | $4.5M | $4.8M | $4.0M | $3.6M | $4.0M | $4.5M | $3.3M | $2.9M | $3.1M | $3.4M | $3.6M | $1.9M |
| Interest expense | — | — | — | — | — | — | — | — | — | — | $1.3M | — |
| Income before taxes | −$63.2M | −$53.1M | −$46.1M | −$42.2M | −$43.8M | −$30.4M | −$33.6M | −$34.6M | −$30.4M | −$31.0M | −$26.8M | −$21.5M |
| Income taxes | — | — | — | — | — | — | $3.4M | — | — | −$3.4M | $4.8M | −$1.9M |
| Net income | −$63.2M | −$53.1M | −$46.1M | −$42.2M | −$43.8M | −$30.4M | −$33.6M | −$34.6M | −$30.4M | −$31.0M | −$26.8M | −$21.5M |
| EBITDA | −$63.1M | −$53.0M | −$45.9M | −$42.2M | −$43.7M | −$30.3M | −$33.5M | −$34.5M | −$30.3M | −$30.9M | −$26.7M | −$21.4M |
| EPS (diluted) | −$0.61 | −$0.52 | −$0.50 | −$0.49 | −$0.51 | −$0.36 | −$0.51 | −$0.60 | −$0.54 | −$0.56 | −$0.49 | −$0.48 |
| Gross margin | — | — | — | — | — | — | 50.0% | — | — | — | 95.3% | — |
| Operating margin | — | — | — | — | — | — | −10,101.1% | — | — | — | −1,614.4% | — |
| Net margin | — | — | — | — | — | — | −9,221.7% | — | — | — | −1,421.0% | — |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in OLMA's financial statements (latest annual report filed March 16, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
OLMA financial results
Olema Pharmaceuticals reported no revenue in fiscal year 2025 (ended December 31, 2025). It had a net loss of $162.5 million. Diluted earnings per share came to −$1.86.
See the OLMA stock overview for the latest quote and news, or the OLMA chart for price history and technical indicators.
OLMA income statement FAQ
Does Olema Pharmaceuticals have revenue?
Olema Pharmaceuticals reported no revenue for fiscal year 2025, which ended on December 31, 2025.
Is Olema Pharmaceuticals profitable?
No. Olema Pharmaceuticals reported a net loss of $162.5 million in fiscal 2025.
How much does Olema Pharmaceuticals spend on research and development?
Olema Pharmaceuticals spent $157.7 million on research and development in fiscal 2025.
What are Olema Pharmaceuticals's earnings per share?
Olema Pharmaceuticals earned $-1.86 per diluted share in fiscal 2025, compared with $-2.21 a year earlier.
When will Olema Pharmaceuticals report its next earnings?
Olema Pharmaceuticals is expected to report results for the quarter ending September 30, 2026 on November 9, 2026 after the market closes.
When does Olema Pharmaceuticals's fiscal year end?
Olema Pharmaceuticals's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on March 16, 2026.